New combo therapy aims to shrink unresectable bile duct tumors
NCT ID NCT07364305
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a treatment for people with advanced bile duct cancer (ICC) that cannot be removed by surgery. The treatment combines chemotherapy given directly into the liver (HAIC) with immunotherapy drugs. The goal is to see if this combination can shrink tumors enough to allow surgery or improve outcomes. About 50 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Eastern Hepatobiliary Surgery Hospital
RECRUITINGShanghai, Shanghai Municipality, 200438, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A lifeline for cancer caregivers: can simple phone support reduce their stress?
- A digital lifeline: could Real-Time symptom tracking transform care for kids with advanced cancer?
- Can a 30-hour e-learning course equip family doctors to deliver better palliative care?
- Can a new nucleotide analogue boost cancer treatment?
- Can a cancer vaccine train the body to fight advanced tumors?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?